Ken Liao
Ningbo University(CN)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Radiopharmaceutical Chemistry and Applications, Biosimilars and Bioanalytical Methods, Monoclonal and Polyclonal Antibodies Research
Most-Cited Works
- → Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling(2006)155 cited
- → Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform(2006)110 cited
- → Wheat Ammonium Transporter (AMT) Gene Family: Diversity and Possible Role in Host–Pathogen Interaction with Stem Rust(2017)59 cited
- → Ligand‐Based and Structure‐Based Investigation for Alzheimer’s Disease from Traditional Chinese Medicine(2014)58 cited
- → Molecular and toxicologic research in newborn hypospadiac male rats following in utero exposure to di-n-butyl phthalate (DBP)(2009)46 cited
- → PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.(2021)44 cited
- → Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).(2021)42 cited
- → Risk‐Based Pharmacokinetic and Drug–Drug Interaction Characterization of Antibody–Drug Conjugates in Oncology Clinical Development: An International Consortium for Innovation and Quality in Pharmaceutical Development Perspective(2021)19 cited
- → Assessing Kinetic Determinants for Metabolism and Oral Uptake of Octamethylcyclotetrasiloxane (D4) from Inhalation Chamber Studies(2008)15 cited
- → PK/PD model‐informed dose selection for oncology phase I expansion: Case study based on PF‐06939999, a PRMT5 inhibitor(2022)14 cited